Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with ...

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate ...

Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast ...

The FDA has granted clearance to an investigational new drug application for CLD-201 for solid tumor treatment, based on ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

Anthony S. Stein, MD, discusses a study of total marrow and lymphoid irradiation 20 Gy and post-transplant cyclophosphamide in acute myeloid leukemia undergoing allogeneic hematopoietic cell ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of ...

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...